Background. Varicella, a contagious infectious disease caused by varicella zoster virus (VZV), can result in hospitalization and, occasionally, death. Varicella virus vaccine live (VVVL [VARIVAX]) was introduced in the United States in 1995.
Varicella (chickenpox), an acute infectious disease caused by varicella zoster virus (VZV), is extremely contagious, with secondary attack rates of up to 90% among household contacts of infected persons [1] . VZV persists as a latent infection in the sensory nerve ganglia, with reactivation causing the recurrent infection of shingles (herpes zoster [HZ] ) [1] . Before vaccine introduction, the average US incidence of varicella was ~4 million cases per year, with >10 000 hospitalizations and ~145 deaths per year attributable to varicella [1] [2] [3] [4] . Recent data indicate that >90% of US children are vaccinated against varicella ( Figure  1 ) [5] , and varicella annual incidence has declined to <350 000 cases, with <1700 hospitalizations and <20 deaths per year [3, 6] .
Varicella virus vaccine live (VVVL; VARIVAX [Oka/Merck]; Merck & Co., Inc., Kenilworth, NJ) was licensed in the United States in May 1995 [7, 8] . In 1996, a single dose of varicella vaccine for children aged 12-18 months was recommended [2] , but despite vaccine effectiveness of 81%, outbreaks continued to occur in populations with high coverage rates [9] . In June 2006, the recommendation was changed to a 2-dose regimen (first dose: age 12-15 months; second dose: age 4-6 years) [2] . VVVL is currently indicated for active immunization for the prevention of varicella in individuals aged ≥12 months [7] . In common with other live, attenuated viral vaccines, use in individuals with primary or acquired immunodeficiency states, any febrile illness or active infection, or pregnancy is contraindicated [7] .
The efficacy of VVVL was established in clinical trials, and its effectiveness has been based on comparisons with historical data [7] . In a study of healthy children who received 1 or 2 doses of VVVL, vaccine efficacy for the 10-year observation period was 94% for 1 dose and 98% for 2 doses (P < .001). Compared with historical data for wild-type VZV (WTV), there was an 80% decrease in the expected number of cases after the 2-dose vaccination [7] .
A 10-year postmarketing safety review showed that VVVL was generally safe and well tolerated [8] . This report reviews 22 years of postmarketing safety data received by Merck, Sharp & Dohme (MSD).
reports from health care providers and consumers. Although ideally all AEs should be reported, this is a voluntary process, with the level of detail dependent upon the individual who submits the report. Despite efforts to solicit additional facts, demographic, medical/clinical, and laboratory information may vary in completeness and accuracy. The database also includes AEs from noninterventional studies and the published literature. The National Childhood Vaccine Injury Act of 1986 [10] requires that certain AEs occurring postvaccination in the United States be reported to the Vaccine Adverse Event Reporting System.
Once received by MSD, AEs are coded using preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA) [11] .
This analysis includes all spontaneous postmarketing and noninterventional study reports submitted by health care providers or reported in the published literature received worldwide during the 22-year period following licensure of VVVL, from March 17, 1995 , through March 16, 2017 (reports received from consumers present in the database were not included in this analysis). The available data are inadequate to reliably estimate the number of exposed individuals; therefore, reporting rates are calculated based on total doses distributed, with the assumption that each patient received 1 dose. Time to AE onset was calculated from the date of vaccination (day 1) to the date of onset of the first reported AE. AE outcome was defined as the outcome provided at the time of the report. Reports of rash (including HZ, HZ-like, varicella, and varicella-like rash) were evaluated between 1 and 42 days postvaccination. The 42-day time frame, based on twice the VZV incubation period of 21 days, represents the upper limit of time during which a vaccinee would be expected to mount an immune response. [5] .
MSD Pregnancy Registry
VVVL is contraindicated during pregnancy. The company recommends that women avoid pregnancy for 3 months after vaccination; however, the Advisory Committee on Immunization Practices (ACIP) recommendation for live varicella vaccine administration advises that pregnancy be avoided for 1 month following each dose of VVVL [2] . However, it is recognized that, despite these contraindications and precautions [7] , vaccination of pregnant women may occur inadvertently. A Pregnancy Registry was established (March 1995) to collect reports of and evaluate the safety and outcomes of women reported to have received VVVL within 3 months before conception or during pregnancy. On October 16, 2013, the Registry was closed to new enrollment [12] ; individuals enrolled before closure were followed until after their estimated delivery date.
Definitions
The MedDRA preferred terms are listed in Supplementary Appendix 1. A report may contain ≥1 AE and includes all AEs reported by that individual. Serious AEs (SAEs) were defined per the International Conference on Harmonisation guidelines [13, 14] . Secondary transmission was defined as the documented presence of Oka/Merck vaccine strain VZV in a nonvaccinated contact of an individual vaccinated with VVVL. Based on European Medicines Agency (EMA) guidelines [15] , potentially immunocompromised patients were identified based on medical histories, concurrent conditions, and concomitant therapies. Samples were analyzed using polymerase chain reaction (PCR) methodology to confirm the presence and type (vaccine strain or wild-type virus [WTV]) of VZV [16] .
RESULTS

Postmarketing Surveillance Data: Overview
During the 22-year evaluation period, >212 million doses of VVVL were distributed worldwide, and 46 855 AE reports were received. Rates of the most commonly reported AEs are presented in Figure 2 . Rates of SAEs fluctuated over time ( Figure 3 ). Central nervous system (CNS) SAEs declined by approximately twothirds during the review period, whereas the incidence of varicella SAEs remained relatively stable during that time.
Reports of AEs of interest, with PCR analysis from all laboratories, are presented in Table 1 . Table 2 presents AEs reported in immunocompromised patients in whom vaccine strain VZV was identified.
Varicella After Vaccination
There were 10 677 reports of 11 095 varicella events (10 751 AEs, 344 SAEs). Time to onset was available for 6692 reports, of which 22% (1471/6692) occurred within 42 days postvaccination. Of the 56% (5927/10 677) of cases with a reported outcome, 93% (5519/5927) were recovered/recovering and 7% (403/5927) had not recovered at the time of reporting; 9 cases resulted in a fatal outcome (Supplementary Appendix 2). Most fatal outcomes occurred in immunocompromised patients, in whom VVVL is contraindicated (see below). Lesion samples (n = 204; more than 1 sample may have been submitted per patient) submitted for PCR testing included 49 from immunocompromised patients (32 vaccine strain VZV, 9 WTV, 4 untypable/no strain identified, and 4 inadequate samples).
Herpes Zoster
Over the evaluation period, 1602 reports of 1803 HZ events were submitted (1646 AEs, 157 SAEs). Of the 1602 reports with c Results include samples that were VZV-positive; however, strain identification was not able to identify either the wild-type virus or vaccine strain virus. Reports in which samples were found to be VZV-positive without strain identification testing are presented in this table. d All samples presented were lesion samples, with the exception of 3 samples: 1 patient had 2 samples submitted for analysis (1 CSF and 1 throat swab); both were found to be negative.
Another patient (a 30-year-old pregnant woman) had a lesion sample identified as vaccine strain; she elected to have a therapeutic abortion, and the products of conception were negative for VZV. e Samples included cerebrospinal fluid and brain tissue.
f Per review of 1 disseminated varicella, CSF was identified to be VZV-positive untyped and interpreted to be vaccine strain based on Oka identified in the lesion, urine, serum, nasopharyngeal swab, and oropharyngeal swab. g Samples included autopsy tissue samples, bronchoalveolar lavage, blood, esophagus tissue, gastric biopsy tissue, liver biopsy tissue, lung biopsy tissue, lymph nodes, mouth swab, nasopharyngeal swab, plasma, products of conception, saliva, serum, throat samples, and urine. 
CNS Events
There were 781 reports that included CNS events, the majority of which were febrile convulsion (35%), seizure (32%), ataxia (8%), and encephalitis (7%) (Supplementary submitted for PCR analysis were reported, including 9 from immunocompromised patients (7 vaccine strain VZV, 1 VZV negative, and 1 untypable/no strain identified).
Disseminated Vaccine-Strain VZV
Disseminated disease caused by the Oka/Merck vaccine strain VZV, with or without visceral involvement, was confirmed by PCR analysis in 39 cases. Eleven cases occurred in immunocompetent individuals, and 28 involved patients who had underlying immunosuppressive conditions and/or who reported concomitant use of immunosuppressant therapies (Tables 2 and 3 ). Among the 11 immunocompetent patients, vaccine strain VZV was identified in cerebrospinal fluid (CSF; n = 10), lesion samples (n = 2), gastric mucosa (n = 1), and saliva (n = 1); among the 28 immunocompromised patients, vaccine strain VZV was identified in lesion samples (n = 18), bronchoalveolar/sputum (n = 8), CSF (n = 6), ocular samples (n = 3), other samples (n = 3), lung biopsy (n = 1), liver biopsy (n = 1), and serum (n = 1).
Pregnancy
All Pregnancy Cases Reported to MSD
Between March 17, 1995, and March 16, 2017, 1216 women were exposed to VVVL during pregnancy and had pregnancy outcomes available for analysis (Table 4) . Timing of exposure was available in 1066/1216 reports, including 883 pregnancies that resulted in 895 liveborn infants (1 set of triplets, 10 sets of twins). Of the 883 reports of live births with known timing of exposure, 288 (32.6%) women received VVVL vaccination before their last menstrual period (LMP), 511 (57.8%) were vaccinated in the first trimester and 84 (9.1%) were vaccinated after the first trimester. Of the women exposed to VVVL before or during pregnancy, congenital anomalies were noted in 56 reports (congenital anomalies include major birth defects as defined by the Metropolitan Atlanta Congenital Defects Program [MACDP]-a population-based tracking system for birth defects among children and infants born to mothers living in metropolitan Atlanta-and congenital anomalies that do not meet MACDP classification as major anomalies), with 14 women exposed before their LMP, 33 exposed in the first trimester, and 9 with unknown time of exposure. Utilizing ACIP recommendations to avoid pregnancy for 1 month after vaccination, 180 of the 288 women were vaccinated <30 days before LMP. Of the 14 reports of congenital anomalies in women exposed before LMP, 6 were vaccinated <30 days before LMP.
MSD Pregnancy Registry
Among the 1522 prospectively enrolled women, there were 966 pregnancy outcomes with 809 live births (819 total infants), none of whom had features consistent with congenital varicella syndrome. Twenty-two reports of major birth defects were submitted. Using the MACDP methodology [17] , including pregnancies that progressed >20 weeks post-LMP, 17 defects occurred among 819 live births, giving a birth prevalence of 2.1 per 100 liveborn infants (95% confidence interval [CI], 1.2-3.3) [1] . Pregnancy outcomes in these 17 women included 16 live births and 1 elective termination at 32 weeks' gestation. The MACDP methodology was revised to include elective terminations after prenatal diagnoses of birth defects at any gestational age (minimum and maximum adjusted defect prevalences were calculated by adding definite prenatal defects and definite plus possible prenatal defects to the hospital-based cases) [18] , which allowed 4 elective terminations at <20 weeks' gestation with a diagnosis of a fetal abnormality to meet the inclusion criteria; the resulting 21 major defects provided a birth defect prevalence of 2.6 per 100 liveborn infants (95% CI, 1.6-3.9). In the general US population, approximately 3% of all births (live births or stillbirths) are diagnosed with major birth defects [19] . Using either methodology, the prevalence of major birth defects in the Registry is similar to that in the general population.
Fatal Outcomes
Fatal outcomes temporally, but not necessarily causally, associated with VVVL were reported in 86 of 46 855 (0.002%) postmarketing reports, including 26 from immunocompromised patients (Figure 4) . Twenty-one reports (24%) provided insufficient information for further discussion. Of the remaining 65 cases (24 in immunocompromised individuals), death was associated with the following: preexisting conditions (n = 17), complications of varicella (n = 11), complications of herpes zoster (n = 2), other infections (n = 9), pulmonary complications (n = 6), cardiac complications (n = 5), CNS (n = 4), and other causes (n = 11) (Supplementary Appendix 2).
DISCUSSION
Although clinical trials are necessary to determine vaccine safety, immunogenicity, and efficacy, postmarketing surveillance is an essential tool to monitor safety profiles postlicensure [20] . The strength of postmarketing surveillance is that it provides information on real-world use in larger populations than is possible with clinical trials, may include populations not included in clinical trials, and identifies less common and/or rare AEs that may not be observed during clinical trials [21] . These strengths are balanced by the limitations of postmarketing surveillance, which relies heavily on voluntary, passive reporting and is often incomplete. Additionally, the number of exposed (vaccinated) persons is an estimation only [22] , and thus calculation of accurate AE incidence rates is limited. Evidence included in AE reports, which includes medical information and diagnostic and laboratory data, is provided by the individual who submits the report, generally without confirmation. The data available in AE reports can be sufficient to provide temporal associations but are generally inadequate to establish causality [23] . In this review, we summarize reports and outcomes collected over >2 decades of postmarketing surveillance of VVVL, with safety surveillance further enhanced by PCR analysis. During 22 years of routine VVVL use, rates of many AEs and SAEs have noticeably decreased, particularly those of varicella and rash. Concerning reports of varicella, most cases occurred >42 days postvaccination, and PCR data suggest that most cases resulted from infection with WTV. However, reports of pyrexia and serious pyrexia appear to have rebounded in recent 
fatal cases (26 immunocompromised)
Varicella, n = 11 (10 immunocompromised) years. This increase may be related to the implementation of programs-such as that undertaken in Italy between 2013 and 2014 [24] , in which parents of a vaccinated child received preprinted diary cards for specific AEs (eg, injection site reactions, fever, convulsions, headache)-that have correlated with an increase in the reporting of vaccination-associated AEs [25] . Changes in coding also likely contributed to the increase in pyrexia reports. In 2016, MSD adopted the European Medicines Agency list of terms for important medical events [26] ; because hyperpyrexia is included in the list, the incidence of pyrexia as an SAE increased almost 3-fold (to 6.14 per million doses between 2015 and 2017), although in the vast majority of reports, medical intervention was not required.
The shift from a 1-dose to a 2-dose vaccination regimen in 2006 was recommended to increase immunity levels, with the second dose added to improve humoral and cellular responses. The introduction of the second dose corresponds with a temporal decrease in the rate of varicella among children and adolescents and a 3.3-fold lower risk of breakthrough disease compared with the prevaccination era [4, 7, 27] . Importantly, overall AE rates did not increase following the introduction of the 2-dose regimen, and no new commonly occurring AEs have been noted in the years since then.
It has been suggested that widespread vaccination may result in decreased maintenance of community immunity, leading to a shift in infections toward older individuals owing to VZV reactivation [2, 28, 29] , but to date, studies examining rates of varicella and HZ in adults in the postvaccination era have reported conflicting results [2, 30] . A recent literature review of severe breakthrough cases resulting in disseminated VZV infection suggested that most cases occurred within 5 years of vaccination-that is, in children rather than in adults [31] . Our data would support this, as the immunocompetent patients in whom disseminated disease developed were children (aged 3-16 years) who developed symptoms 2-14 years after vaccination.
Although systemic postvaccination infections are rare in immunocompetent patients, we report 11 cases of Oka/Merck vaccine strain VZV in immunocompetent patients. Secondary transmission is also an uncommon event but has the potential to cause complications in a susceptible contact, such as an immunocompromised or pregnant individual. In prevaccinationera studies, the secondary infection rate of varicella among susceptible children ranged from 61% to 100% [32] [33] [34] . In the current analysis, 357 cases (0.0001% of >212 million doses) of potential secondary transmission were recorded, although 38/68 analyzed by PCR proved to be WTV. AEs during pregnancy were uncommon; the prevalence of major birth defects in the Pregnancy Registry was similar to that observed in the general population, and no new safety concerns among susceptible women exposed to the varicella vaccine were identified.
VZV is neurotropic, with recognized presentations including meningoencephalitis, hemiparesis, hemiplegia, myelitis, and peripheral neuritis [35, 36] ; however, in general, neurologic complications reported after vaccination were rare. In this analysis, the most commonly reported CNS AEs were seizures/ convulsions, which are noted as potential AEs in the VVVL prescribing information [7] .
Overall, 86 deaths were reported after VVVL vaccination; however, almost 25% of reports contained insufficient data to identify the cause of death. Immunocompromised individuals are at the highest risk for a fatal varicella-related outcome, and it is important to reiterate that the potential risk of disseminated disease contraindicates VVVL (and other live viral vaccines) in immunosuppressed or immunodeficient individuals, including those on immunosuppressive therapy [7] . Overall, 13 deaths were associated with varicella or HZ, 12 of which occurred among immunocompromised patients. One varicellaassociated fatality occurred in an immunocompetent patient and was confirmed by PCR as being due to WTV. Reports of HZ were uncommon (~1 report per 200 000 doses), and although most patients recovered, both cases of HZ with a fatal outcome involved immunocompromised individuals. Oka/Merck vaccine strain VZV was detected from specimens obtained from all 32 immunocompromised patients reporting disseminated disease after receiving VVVL, reinforcing the contraindication for vaccination in these individuals.
CONCLUSIONS
This 22-year analysis, the largest to date, presents the worldwide safety profile as based on spontaneous postmarketing reports for VVVL vaccine after distribution of >212 million doses of vaccine. In addition to VVVL's proven efficacy profile, these data confirm that VVVL is safe and generally well tolerated. Results were consistent with safety trends reported in previous analyses [8, 37] , and the overall safety profile of VVVL is consistent with findings from pivotal clinical trials. MSD continues to conduct routine postmarketing surveillance to identify any temporal associations between VVVL vaccine and AEs in order to inform public health practice and ensure the integrity of its product.
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